Actively Recruiting
SerpinB3 Expression, PAR2 and SCCA-PD Polymorphism in Acute Respiratory Distress Syndrome
Led by University of Padova · Updated on 2025-03-05
40
Participants Needed
1
Research Sites
304 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The Acute Respiratory Distress Syndrome (ARDS) is a systemic syndrome characterized by severe respiratory failure, inflammation, loss of aerated tissue and high mortality. Recently, significant efforts have been made to phenotype ARDS patients through a wide range of new biomarkers and imaging indices with the goal of developing personalized treatments based on patient's biophenotypization. Recent literature demonstrates, both in vitro and in vivo but not yet in ARDS patients, that the serine protease inhibitor(SERPIN)-B3 plays a crucial role in the pathological mechanism of pulmonary fibrogenesis, and, similarly, protease-activated receptors(PAR2) is highly involved in this aberrant inflammatory response. Consequently, studying the expression of SERPINB3 (including SCCA-PD polymorphism) and PAR2, in association with a detailed clinical and biomolecular phenotypization, could allow new insights into the pathophysiological mechanisms of lung injury during ARDS.
CONDITIONS
Official Title
SerpinB3 Expression, PAR2 and SCCA-PD Polymorphism in Acute Respiratory Distress Syndrome
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with Acute Respiratory Distress Syndrome (ARDS)
- Receiving invasive mechanical ventilation (IMV)
You will not qualify if you...
- Under 18 years of age
- Pregnant
- Do not consent to participate in the study
- Contraindications to fiberoptic bronchoscopy or bronchoalveolar lavage (BAL)
- Have chronic inflammatory skin conditions
- Have chronic lung diseases
- Have inflammatory respiratory diseases
- Have certain cancers such as squamous cell carcinoma of the cervix or esophagus, lung adenocarcinoma, breast adenocarcinoma, pancreatic adenocarcinoma, or hepatocellular carcinoma
- History of active or passive smoking
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Azienda Ospedaliera di Padova
Padova, PD, Italy, 35126
Actively Recruiting
Research Team
A
Annalisa Boscolo, Professor
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here